#### **Background**

Article 120(3) of (EU) 2017/745 (MDR) allows that devices in accordance with 93/42/EEC (MDD) can continue to be placed on the market if:

- The relevant MDD certificates are valid
- The devices continue to be compliant with MDD
- The following requirements of the MDR are met:
  - o post-market surveillance (including PPRC),
  - o vigilance,
  - o registration of site and products, and
  - no significant changes to the design and the intended purpose.

This checklist is used to determine if the change in the intended purpose or design of the device is a significant as per article 120(3).



#### Requirements and responsibilities

This guidance is used for MDR article 120(3) and is to be completed in addition to the requirements in NBOG BPG 2014-3 "Guidance for manufacturers and Notified Bodies on reporting design changes and changes of quality system".

When using this checklist, the following mandatory instructions apply:

- Any change made to the approved design or intended purpose of an existing MDD product under article 120(3) of MDR must be assessed within this checklist.
- This checklist is to be approved by the person responsible for regulatory compliance (PRRC).
- The checklist consists of 6 flowcharts (taken from MDCG 2020-3):
  - Main Chart
  - Flow Chart A: Intended purpose
  - Flow Chart B: Design and performance specification
  - Flow Chart C: Software
  - Flow Chart D: Material
  - Flow Chart E: Sterilization method or packaging design
- All charts must be completed for each change. If a chart is not applicable, it is to be justified in the footer of the chart.
- If a change includes multiple changes, each change must be assessed on its own. In addition, the cumulative impact of changes must be assessed.
- Examples of significant and non-significant changes and further guidance are given in MDCG Guidance 2020-3.


- If the assessment concludes that the change is significant, the change process shall be discontinued. Decision must be made by top management if and how to follow-up the change.
- The notified body will have to be notified of any change for class III or active implantable devices.
  - Using this checklist, we will determine if the change is significant or not.
  - Non-significant changes will be notified to our notified body. The notified body will review and agree or disagree to our notification.
  - The change can only be implemented once the notified body agreed that the change is non-significant.
  - The non-significant change will be listed continuously in the list of changes.
- All non-significant changes for class I and class II devices will be listed continuously in the list of changes
  - The list of non-significant changes to class I and class II products will be submitted, if requested, to the notified body ahead of the annual surveillance audits.

#### References

[1] (EU) 2017/745 MDR


[2] NBOG BPG 2014-3 "Guidance for manufacturers and Notified Bodies on reporting design changes and changes of quality system" [3] MDCG 2020-3 Guidance on significant changes regarding the transitional provision under Article 120 of the MDR with regard to devices covered by certificates according to MDD or AIMDD

#### Main chart (Part 1)




Main chart (Part 2)

#### Main chart (Part 2)



Conclusion:	
The change is significant  yes	no

#### Flow Chart A: Intended purpose



#### Flow Chart B: Design and performance specification


#### Chart B \* Itshall <u>not</u> betakeninto accounthowthe changeis FromMain Chart: achieved. A changein specification Change of theDesignorPerformance Specification\* maybetriggeredby, but isnot limited to, changeof hardwareor software, includingchangeof a component. В1 Does the change require \*\* Compare Yes further clinical or MEDDEV 2.7/1 rev.4 usability data to support forfurtherguidance safety and perfor mance? No Yes Do new risks require control measures or are existing risks negatively affected? No Change of built-in control mechanism, operating principles, source of energyor alarms No Return toMain Chart The changeisconsidered QuestionC (or move directly to E significantper MDR Art. 120(3) if Chart D was previously used) Conclusion: ☐ The flowchart is not applicable because:

□no

The change is significant yes


#### Flow Chart C: Software (Part 1)

# Chart C



Software (Part 2)


#### Flow Chart C: Software (Part 2)




#### Conclusion:

☐ The flowchart is not applicable because:	
The change is significant	

#### Flow Chart D: Material (Part 1)




#### Flow Chart D: Material (Part 2)



#### Conclusion:

The flowchart is not applicable because:
The change is significant  yes  no

#### Flow Chart E: Sterilization method or packaging design



Conclusion:
The change is considered significant
☐ yes ☐ no
In case of multiple changes within one assessment: The cumulative impact of change is considered significant
yes no, because (justify):
The product is a class III product and/or active implantable device. Notification to notified body will have to be notified prior to implementation.
Change Notification number:
The product is a class I or class II device and notification to notified body is not needed prior to implementation.
Approval by PRRC
Date / Name / Signature